Abstract. The majority of human endometrial and ovarian cancers express receptors for GnRH type I (GnRH-I). Their proliferation is time-and dose-dependently reduced by GnRH-I and its analogs. GnRH-I analogs activate a phosphotyrosinephosphatase (PTP) and inhibit EGF-induced mitogenic signal transduction. Recently we found that GnRH type II (GnRH-II) and its agonist [D-Lys 6 ]GnRH-II also have antiproliferative effects on these tumor cells which are significantly greater than those of GnRH-I agonists. In a more recent study, we showed that the antiproliferative activity of GnRH-II on human endometrial and ovarian cancer cell lines is not mediated through the GnRH-I receptor. The underlying signal transduction mechanisms of GnRH-II are still unknown. In this study we showed that the mitogenic effects of growth factors in endometrial and ovarian cancer cell lines were counteracted by GnRH-II agonist GnRH-II still activated PTP and inhibited the EGF-induced mitogenic signal transduction. These data indicate, that the effects of GnRH-II are not due to a cross-reaction with the GnRH-I receptor. In conclusion these data suggest that the signaling of GnRH-II agonist [D-Lys 6 ]GnRH-II is comparable to that of GnRH-I analogs.
Introduction
The expression of gonadotropin releasing hormone (GnRH-I) and its receptor as a part of a negative autocrine/paracrine mechanism of cell proliferation has been demonstrated in a number of malignant tumors, including cancers of the endometrium, ovary and breast (1) . In these cancers the in vitro proliferation can be inhibited by agonistic and/or antagonistic analogs of GnRH-I in a dose-and time-dependent manner (1) (2) (3) (4) (5) . The classical GnRH-I receptor signal transduction mechanisms, known to operate in the pituitary, are not involved in the mediation of antiproliferative effects of GnRH-I analogs in cancer cells (1) . The GnRH-I receptor rather interacts with the mitogenic signal transduction of growth factor receptors and related oncogene products associated with tyrosine kinase activity via activation of a phosphotyrosine phosphatase (PTP) counteracting the EGF-induced auto-tyrosine phosphorylation of the EGF receptor. Thus, the activity of the extracellular regulated kinases 1 and 2 (ERK1/2) is decreased. Moreover the EGF-induced expression of the immediate early gene c-fos and its protein is reduced. As a result cell proliferation is decreased (6) (7) (8) .
Recently, we could show that GnRH type II (GnRH-II) has antiproliferative effects in human endometrial and ovarian cancer cell lines that are significantly greater than those of the superactive GnRH-I agonist Triptorelin (9, 10) .
In the ovarian cancer cell line SKOV-3, which does not express GnRH-I receptors, GnRH-I agonist Triptorelin has no effects on cell proliferation (11) , whereas GnRH-II has strong antiproliferative effects. It might be speculated that, in addition to the GnRH-I system, a second GnRH-system exists in human cancers. Recently we showed that in cell lines affected by both, GnRH-I agonist Triptorelin and GnRH-II agonist [DLys 6 ]GnRH-II, the effects of the former were abrogated after GnRH-I receptor knockout, whereas those of GnRH-II persisted (9) . These findings suggest that the antiproliferative effects of GnRH-II are not mediated through the GnRH-I receptor. The mechanisms underlying the antiproliferative effects of GnRH-II are unknown. In this study we have assessed whether or not GnRH-II signal transduction is comparable to that of GnRH-I analogs.
Materials and methods
Cell lines and culture conditions. The human endometrial cancer cell lines used were derived from an endometrial adenocarcinoma (Ishikawa) (12) or a moderately differentiated papillary adenocarcinoma (Hec1A) (13) . The human ovarian cancer cell lines used were derived from a poorly differentiated serous adenocarcinoma (EFO-21) (14) or an adenocarcinoma derived from ascites (SKOV-3) (15). They were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) or the sources as described previously (2, 3) . The cells were cultured at 37˚C in a humidified atmosphere of 5% CO 2 in air as described previously (2) (3) (4) .
For determination of EGF-induced c-fos mRNA expression, the cells were cultured in the absence of fetal calf serum (FCS) and phenol-red for 72 h. The quiescent cells were treated with 100 nM human recombinant EGF (SigmaAldrich, Deisenhofen, Germany) for 30 min with or without previous treatment ( Phosphatase assay. The cells were plated in 75-cm 2 dishes at a density of 5x10 5 cells and grown under standard conditions. After 3-4 days, when the confluence of each dish reached 90%, the cells were incubated with FCS-free and phenol-redfree medium for 48 h. Treatment with 100 pM, 1 nM, 100 nM or 10 μM of the GnRH-II agonist [D-Lys 6 ]GnRH-II (PSC Heidelberg) for 1 h followed. The reactions were stopped by washing with 5 ml of ice-cold PBS. After washing, the cells were detached immediately with 2.5 ml of a solution containing 0.5 g Trypsin (Biochrom, Berlin, Germany) and 5 mmol EDTA in 1 l PBS/BSA, counted and lysed in a buffer containing 60 mM sodium acetate, pH 5.2, 5 mM ß-mercaptoethanol and 1% Triton X-100. Endogenous phosphate was removed using Sephadex G-25 spin colums (Promega Corp., Madison, WI).
Tyrosine phosphatase activity was measured using a tyrosine phosphatase assay system (Promega Corp.), initially described by Harder et al (16) . The synthetic PTP-specific phosphopeptide provided with this assay is END(pY)INASL (17) . The assay was performed with 10 μg protein, initiated by the addition of the enzyme, and incubated at 37˚C for 15 min. The reaction was stopped by adding molybdatemalachite-green solution.
mRNA isolation and cDNA synthesis. mRNA was isolated from cells grown in a monolayer using the Qiagen RNeasy Mini kit (Qiagen, Hilden, Germany). The concentration of poly(A)mRNA in each sample was determined by photospectrometry. First-strand cDNA was generated by reverse transcription of 1 μg of mRNA using p(dT)15 primers (Roche Diagnostics, Mannheim, Germany) with a Superscript™ preamplification kit, according to the instructions of the supplier (Invitrogen, Life Technologies, Karlsruhe, Germany).
After determining the concentration of the cDNAs, the samples were used for semi-quantitative PCR analysis. The integrity of the samples was tested by RT-PCR of the housekeeping gene GAPDH (forward primer: 5'-CAT CAC CAT CTT CCA GGA GCG AGA-3', backward primer: 5'-GTC TTC TGG GTG GCA GTG ATG G-3').
PCR amplification. cDNAs (1 μg) were amplified in a 50-μl reaction volume containing 10 mmol/l Tris-HCl (pH 8.3), 50 mmol/l potassium chloride, 1.5 mmol/l magnesium chloride, 200 μmol/l of each of the NTPs, 200 μmol/l of primers specific for a 483-bp fragment of the human c-fos mRNA (forward primer, 5'-GAG ATT GCC AAC CTG CTG AA-3'; backward primer, 5'-AGA CGA AGG AAG ACG TGT AA-3') and 1.25 U Taq polymerase (Roche, Mannheim, Germany) (6) . The reaction was performed in an Applied Biosystems DNA thermal cycler 2400 (Weiterstadt, Germany). Between 24 (EFO-21 and SKOV-3) and 26 (Ishikawa and Hec1A) cycles were carried out: denaturation 94˚C for 30 sec, annealing at 54˚C for 30 sec, followed by extension at 72˚C for 60 sec. To compare the expression levels of c-fos, PCR reactions using primers for the housekeeping gene GAPDH were performed (see above). Seventeen cycles were carried out: denaturation 94˚C for 60 sec, annealing at 60˚C for 60 sec, followed by extension at 72˚C for 60 sec. The PCR products of both reactions were separated by gel electrophoresis in 1.5% agarose and visualized by ethidium bromide staining on a UV transilluminator.
Western blotting. The cells were plated in 75-cm 2 dishes at a density of ~10 6 cells and grown under standard conditions. After achieving a confluence of ~70-80%, the culture medium was changed to FCS-free and phenol-red-free medium for 24 h (MAPK) or 48 h (c-Fos). To induce MAPK (ERK1/2) and c-Fos activity, cells were treated with 100 nM of human recombinant EGF (Sigma-Aldrich) for 30 or 15 min without or with previous treatment (15 min or 1 h) with 10 μM of the GnRH-II agonist [D-Lys 6 ]GnRH-II. After incubation, cells were detached with 2.5 ml of a solution containing Trypsin (0.5 g) (Biochrom) and 5 mmol EDTA in 1 l PBS/BSA. Protein per sample (5 μg) was used and diluted to a final volume of 40 μl with Laemmli-buffer, containing 519 mM DTT (Dithiothreitol, Sigma-Aldrich), 69 mM sodium dodecyl sulfate (SDS), 0.1% Triton X-100, 62.5 mM Tris/HCl pH 6.8 and 75 nM bromphenol blue. The cell lysates were separated on SDS-PAGE (10% acrylamide/N'N'-bis-methyleneacrylamide, AppliChem GmbH, Darmstadt, Germany) under reducing conditions and transferred to nitrocellulose membranes (Hybond™-ECL™ nitrocellulose membrane, Amersham Bioscience). The nitrocellulose membranes were blocked with 5% instant skimmed milk powder, spray-dried (Naturaflor, Töpfer GmbH, Dietmannsried, Germany) in TBST (137 mM NaCl, 2.7 mM KCl, 0.1% Tween-20, 25 mM Tris/Cl, pH 7.4) for 1 h at RT, washed with TBST and then incubated at 4˚C overnight with rabbit polyclonal anti-ACTIVE™MAPK pAb, pTEpY (Promega Corp., Mannheim, Germany) or polyclonal rabbit anti-c-Fos (Abcam, Cambridgeshire, UK) in a 1:5000 or 1:200 dilution in TBST. After washing three times with TBST, specifically bound antibody was detected using the ECL™plus Western blot analysis (Amersham Biosciences, UK). The bands were analyzed using the Kodak 1D image system (Kodak, New Haven, CT).
GnRH-I receptor knockout.
A 43-bp fragment of the human GnRH-I receptor cDNA was cloned in antisense orientation (50-CT AGA ACC ATG GAC TGT CCG ACT TTG CTG TTG CTT TTC AAA GC-30) into the NheI/SalI sites of the eukaryotic expression vector, pIRES (Clontech, Palo Alto, CA, USA), to produce the pGnRH-I receptor-antisense vector. Cells were grown to ~50% confluence in 75-cm 2 dishes. Transfections were performed using Superfect liposome reagents and following the manufacturer's instructions (Qiagen). After 12 h, transfected cells and non-transfected control cells were treated with the GnRH-I agonist Triptorelin (100 nmol/l) to induce GnRH-I receptor protein internalization. Six hours later, the cells were incubated with FCS-free and phenol-redfree medium for 24 h followed by treatment with 100 pM, 1 nM, or 100 nM of the GnRH-II agonist [D-Lys 6 ]GnRH-II for 1 h. Reactions were stopped by washing with 5 ml of icecold PBS. PTP assays were conducted as described above. 
Results

Effects of [D-
Effects of [D-Lys 6 ]GnRH-II on EGF-induced MAPK (ERK1/2) activity. We analyzed the effects of [D-Lys
6 ]GnRH-II on the EGF-induced activity of the extracellular regulated kinases 1 and 2 (ERK1/2). To quantify phosphorylated ERK1/2, a polyclonal rabbit anti-ACTIVE™MAPK pAb was used, which detects phosphorylated ERK1 (44 kDa) and ERK2 (42 kDa). By cultivation of the cells under serum-and phenol-red-free conditions for 72 h, MAPK activity was downregulated to basal expression levels (control = 100%) (Fig. 2) . Treatment of the quiescent cells with EGF (100 nM) for 15 min resulted in a significant increase of MAPK activity in all cell lines tested (Fig. 2) . After treatment with GnRH-II agonist [D-Lys 6 ]GnRH-II (10 μM) for 15 min, EGF-induced MAPK activity was abrogated (Fig. 2) .
After EGF treatment (100 nM) for 15 min the activity of MAPK in the GnRH-I and GnRH-II receptor-positive endometrial cancer cell line Ishikawa was increased to 286.0±56.9% of control (P<0.05 vs control) ( Fig. 2A) . Additional treatment with GnRH-II agonist [D-Lys 6 ]GnRH-II (10 μM) for 15 min reduced the EGF-induced increase of MAPK activity to 133.6±21.5% (P<0.01 vs EGF). In the GnRH-I receptornegative but GnRH-II receptor-positive ovarian cancer cell line SKOV-3 EGF treatment resulted in an increase of MAPK activity to 161.2±23.9% (P<0.05 vs control) (Fig. 2B) GnRH-II to analyze whether or not GnRH-II has comparable effects.
After cultivation of the cells under serum-and phenol-redfree conditions for 72 h, the c-fos expression of all analyzed cell lines was downregulated to basal expression levels (control = 100%) (Fig. 3) . Treatment of the quiescent cells with 10 μM [D-Lys 6 ]GnRH-II alone had no effect on c-fos expression (Ishikawa: 97.4±23.5% of control, P>0.05 vs control; SKOV-3: 134.0±24.1% of control, P>0.05 vs control) (Fig. 3) . Treatment of the quiescent cells with 100 nM EGF (30 min) resulted in a marked increase of c-fos expression levels in all cell lines tested (Ishikawa: 579.2±131.5% of control, P<0.001 vs control; SKOV-3: 972.4±284.0% of control, P<0.05 vs control) (Fig. 3) .
To analyze whether [D-Lys
6 ]GnRH-II is able to affect EGFinduced c-fos expression, quiescent cells were kept for 60 min in the absence or presence of the GnRH-II agonist [DLys 6 ]GnRH-II (10 μM) before they were incubated for 30 min with 100 nM EGF. The pre-treatment with [D-Lys 6 ]GnRH-II (10 μM) dramatically reduced the EGF-induced c-fos expression. In the GnRH-I and GnRH-II receptor-positive endometrium cancer cell line Ishikawa the EGF-induced c-fos expression was reduced from 579.2±131.5% of control to 188.1±41.2% of control (P<0.001) (Fig. 3A) . In the GnRH-I receptor-negative but GnRH-II receptor-positive ovarian cancer cell line SKOV-3 the EGF-induced c-fos expression was reduced from 972.4%±284.0% of control to 675.0%±230.8% of control (not significant) (Fig. 3B) .
To analyze whether GnRH-II agonist [D-Lys 6 ]GnRH-II treatment also affects c-Fos protein synthesis, quiescent cells were treated as described above. The amount of c-Fos protein was evaluated by SDS-PAGE and Western blotting of the cell lysates. Fig. 4 shows that a protein band of 62 kDa, corresponding to c-Fos protein, is present in the cell lysates. In the serum-starved cells the amount of c-Fos protein was small (control = 100%). Treatment of the quiescent cells with 10 μM [D-Lys 6 ]GnRH-II alone had no effect on c-Fos protein expression. The amount of c-Fos protein was increased after EGF treatment (Fig. 4) . Pre-treatment with [D-Lys 6 ]GnRH-II (10 μM) reduced the EGF-induced c-Fos protein expression (not significant).
Effects of [D-Lys 6 ]GnRH-II on PTP activity after GnRH-I receptor knockout. To assess whether the GnRH-II agonist [D-Lys
6 ]GnRH-II-induced signaling in endometrial and ovarian cancer cells is mediated through GnRH-I receptor, we analyzed the activation of PTP after knockout of GnRH-I receptor expression. Knockout of the GnRH-I receptor protein was controlled by immune cytochemistry using a monoclonal mouse anti-human GnRH-I receptor antibody and immunoblotting using a polyclonal rabbit anti-human GnRH-I receptor antiserum (18) . After internalization of the GnRH-I receptor induced by the GnRH-I agonist Triptorelin, a high density of novel synthesis of GnRH-I receptor protein, seen as GnRH-I receptor antigenicity, was observed in non-transfected cells, whereas transfected cells showed only slight GnRH-I receptor antigenicity. As early as 1 day after knockout of GnRH-I receptor expression, GnRH-I receptor protein antigenicity was significantly reduced in comparison with the control. After 2 days, GnRH-I receptor protein was no longer detected.
After knockout of GnRH-I receptor expression, GnRH-II agonist [D-Lys 6 ]GnRH-II still activated PTP and inhibited the EGF-induced mitogenic signal transduction, whereas the effects of GnRH-I agonist Triptorelin were abrogated. 
Discussion
Our data demonstrate that after the binding of GnRH-II to its receptor the EGF-induced signal transduction in human ovarian and endometrial cancer cells is inhibited. Direct activation of a phosphotyrosine-phosphatase (PTP) by GnRH-II agonist [D-Lys 6 ]GnRH-II counteracts the EGF-induced auto-tyrosinephosphorylation of EGF receptors. Thus, the activity of the mitogen-activated protein kinases (MAPK) ERK 1/2 (extracellular regulated kinases 1 and 2) is decreased. Moreover the EGF-induced expression of the immediate early gene c-fos and its protein is reduced. The signal transduction mechanisms of GnRH-II agonist [D-Lys 6 ]GnRH-II mediating the antiproliferative effects seem to be comparable to that of GnRH-I analogs. However, in contrast to GnRH-I agonists, GnRH-II agonist [D-Lys 6 ]GnRH-II does not activate nucleus factor κB (NF-κB) and therefore does not protect the cancer cells from apoptosis (unpublished data).
Our results are supported by a recent study showing inhibition of cell proliferation in human breast cancer cells after treatment with GnRH-I agonist Triptorelin or GnRH-II agonist [D-Lys 6 ]GnRH-II. EGF-induced auto-tyrosinephosphorylation of EGF-receptors and activation of ERK-1/2 were blocked by GnRH-I and GnRH-II agonists (19) .
Recently we showed that both, GnRH-II agonist [DLys 6 ]GnRH-II and GnRH-I antagonist Cetrorelix, had strong antiproliferative effects in the GnRH-I receptor negative human ovarian cancer cell line SKOV-3 (9,10). After knockout of GnRH-I receptor expression the antiproliferative effects of GnRH-I agonist Triptorelin on former GnRH-I receptorpositive endometrial and ovarian cancer cell lines were abrogated, whereas the growth inhibitory effects of the GnRH-I antagonist Cetrorelix and of GnRH-II agonist [DLys 6 ]GnRH-II were still the same as observed in nontransfected cells (9) . We also demonstrated that treatment of GnRH-I receptor knockout cell lines with GnRH-I agonist Triptorelin could not reduce cell proliferation. After treatment with GnRH-II agonist [D-Lys 6 ]GnRH-II the cell number was decreased in all cell lines investigated (P<0.001 vs control) (9) . Therefore, we assume that a functional GnRH-II receptorligand mechanism or a related mechanism, which is activated by GnRH-II agonist [D-Lys 6 ]GnRH-II or GnRH-I antagonist Cetrorelix, exists in human cancer cells. It is reasonable to speculate that this putative GnRH-II system might be comparable with the GnRH-I system of a negative autocrine mechanism of cell proliferation.
The mammalian GnRH-II receptor system is well characterized. The non-human primate GnRH-II receptor was cloned and detected in all tissues analyzed, organs and carcinomas (20, 21) . Functional analysis of the monkey GnRH-II receptor was performed. These investigations discovered that GnRH-II was active in the nanomolar range, which supported evidence that its receptor is functional (22) . GnRH-II was ~400-fold more active than GnRH-I, which indicates the specificity of the interaction between GnRH-II and its receptor.
The existence of an independent GnRH-II receptor system in non-human primates might be an argument for the occurrence of a similar system in humans. But until now there has been neither success in cloning nor in sequencing the full-length human GnRH-II receptor, which is known to be a member of the 7 transmembrane (TM) receptor family (10, 21, 23, 24) . Probably, the functional GnRH-II receptor is expressed in a variety of splice variants (22) . In this context there are two possibilities: firstly, that the GnRH-II receptor mRNA is expressed, encodes either 5 or 7 TM domains; or secondly, that a GnRH-II responsive complex is formed by the GnRH-I receptor and fragments derived from the GnRH-II receptor. All considerations lead to the conclusion that if a functional GnRH-II receptor is expressed in human tissues, it might be a 5 TM domain receptor, lacking the TM regions I and II (22) . The existence of functional 5 TM G-protein coupled receptor (GPCR) mutants of chemokine receptors, where the N-terminal segment is connected directly to the transmembrane domain 3 as a result of a deletion of the transmembrane domains 1 and 2, is reported by Ling et al (26) . Morgan et al discovered that the human GnRH-II receptor is also expressed in a variety of splice variants but a functional transcript could not be shown (25) . This would support the results of the GnRH-II receptor mRNA detected and described in previous studies (10, 25) , where the receptor is suspected to be non-functional because of a stop codon in the second exon. Van Biljon et al have recently cloned a GnRH-II receptor transcript from human sperm, consisting of the three exons required for a full length receptor protein (27) . This transcript also includes a stop codon and a frame shift. Although this would suggest that the gene is a transcribed pseudogene, there are several lines of evidence for a functional role of GnRH-II receptor in human sperm and testis.
Recent studies from our laboratory demonstrated the first clear evidence for the existence of a GnRH-II receptor-like protein (18) . To identify the protein as a GnRH-II specific binding site we used the photo-affinity-labeling technique and to confirm our results, competition experiments were performed. These experiments and also proliferation assays made in previous studies (9, 10) suggest the existence of a specific GnRH-II binding site in human cancer cells, which might be the putative GnRH-II receptor. Due to our present results that show inhibition of EGF receptor signal transduction after treatment with GnRH-II agonist [D-Lys 6 ]GnRH-II, even after knockout of GnRH-I receptor expression, it seems reasonable to speculate that an additional GnRH-II responsible receptor system exists in human endometrial and ovarian cancer cells. In contrast to our results, Kim et al (28) demonstrated that transfection of short-interfering RNA to abrogate GnRH-I receptor gene expression reversed GnRH-I-and -II-induced antiproliferative effects. These results indicate that GnRH-I and GnRH-II induce their antiproliferation through the GnRH-I receptor. We do not have an explanation for this discrepancy. However, it is possible that, in cells in which the GnRH-I receptor but not the putative GnRH-II receptor is expressed, both, GnRH-I and GnRH-II, activate GnRH-I receptor signal transduction. In addition it is possible that, in cells in which the GnRH-I receptor and the putative additional receptor for GnRH-II are coexpressed, a cross-talk between the signalling of both receptors might take place.
In conclusion, our findings show that in the cell lines used in the present study a putative GnRH-II receptor system might be similar to the well-known GnRH-I receptor system. The antiproliferative effects are mediated through an interaction with the growth factor-induced mitogenic signaling. We demonstrated that GnRH-II agonist [D-Lys 6 ]GnRH-II inhibits the EGF-induced auto-tyrosine-phosphorylation of EGFreceptors by activation of a PTP. Therefore, the proteins further downstream, such as ERK1/2 and c-Fos, are decreased in their activity or expression. Consequently, there is a reduction in cell proliferation. After knockout of GnRH-I receptor expression, GnRH-II agonist [D-Lys 6 ]GnRH-II still activates PTP and inhibits the EGF-induced mitogenic signal transduction. Therefore, the effects of GnRH-II are not due to a cross-reaction with the GnRH-I receptor.
